gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · BIOHealthcareLab Analytical Instruments

Bio-Rad Laboratories, Inc.Class A (BIO)

$379.99+1.35%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$379.60▲ 21.89% in range
Nov 3, 2025Low $241.71 · High $390.34Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Bio-Rad Laboratories, Inc.Class A closed at $379.99 on Nov 4, up 1.35%, 2.7% below its 52-week closing high. Volume of 281.8K shares was 1.25× its 20-day average (above normal).

Split-adjusted performance: +3.0% over one month, +46.7% over six months, +22.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $651M, down 0.1% from a year earlier, with a net margin of 57.1%.

Short interest was 1.1M shares at the Oct 15 settlement, down 7.2% from the prior report (5.9% of float, 4.8 days to cover).

Market cap$10.16B26.7M shares
Revenue · quarter$651.0M−0.1% YoY
Diluted EPS$13.85+18.7% YoY
P/E · TTM45.7×P/S 3.9×
Net margin57.1%Gross 53.1%
Dividend yieldNone
52-week range241.71 – 390.34−2.7% from high
Volume281.8K1.25× 20-day avg
Volatility · 60d27.9%Annualised
Short % of float5.9%4.8 days to cover
Net cash$414.8MCash $1.62B
Next earnings—Not scheduled
Split-adjusted performance
1W −1.3%1M +3.0%3M +11.0%6M +46.7%YTD +25.4%1Y +22.0%3Y +41.1%5Y −50.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum60
Revenue growth26
Net margin100
Value (low P/E)—
Size71

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short1.1M−7.2% vs prior
Days to cover4.8Settled Oct 15
% of float5.9%
Short vol. 10d66.7%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BIOBio-Rad Laboratories$379.99+1.35%+46.7%−0.1%57.1%45.7$10.16B
BIO.BBio-Rad Laboratories$379.50+4.22%—−0.1%57.1%45.6$10.15BCompare
AVTRAvantor$15.65+0.38%+85.6%+4.6%12.0%31.4$10.60BCompare
BRKRBruker$63.79+12.90%+50.8%+5.2%−7.5%—$9.72BCompare
TXG10x Genomics$67.52+3.42%+196.9%−12.6%−11.9%—$8.80BCompare
RVTYRevvity$159.43−2.48%+60.9%+1.3%7.1%74.9$17.79BCompare
ILMNIllumina$226.54−4.90%+58.9%+4.2%19.5%38.3$34.25BCompare
MTDMettler-Toledo International$1,723.24+1.48%+29.9%+4.5%22.7%38.1$34.53BCompare
WATWaters$467.60+1.67%+33.8%+113.4%−8.3%276.5$45.94BCompare

News about Bio-Rad Laboratories

All news →
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for NowZacks Investment Research · Sep 23, 2026NeutralWhy Elliott Sees Hidden Billions Inside Bio-Rad LaboratoriesBenzinga · May 18, 2026▲ Positive

Quick answers

What does Bio-Rad Laboratories, Inc.Class A do?
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories.
What is BIO's market cap?
$10.16B, based on the Nov 4 close of $379.99.
What is BIO's P/E ratio?
45.7× trailing-twelve-month earnings of $222.40M.
Does Bio-Rad Laboratories, Inc.Class A pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BIO is sold short?
1.1M shares, 5.9% of float, as of Oct 15, 2026.
What sector is BIO in?
Healthcare, in the Lab Analytical Instruments industry.

About Bio-Rad Laboratories

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

HQ: Hercules, CA7,450 employeesListed Feb 29, 1980bio-rad.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology